Sarcopenia Market Size, Share, Growth Analysis, 2032

Sarcopenia Industry Prospective:

The global sarcopenia market size was worth around USD 3019.14 million in 2023 and is predicted to grow to around USD 4855.01 million by 2032 with a compound annual growth rate (CAGR) of roughly 5.42% between 2024 and 2032.

Request Free Sample

The report covers a forecast and an analysis of the sarcopenia market on a global and regional level. The study provides historical data from 2018 to 2022 along with a forecast from 2024 to 2032 based on revenue (USD Million). The study includes drivers and restraints for the sarcopenia market along with the impact they have on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the sarcopenia market on a global level.

In order to give the users of this report a comprehensive view of the sarcopenia market, we have included a competitive landscape and an analysis of Porter’s Five Forces model in the market. The study encompasses a market attractiveness analysis, where supplement type, distribution channel, and regional segmentation are benchmarked based on their market size, growth rate, and general attractiveness.

Request Free Sample

Sarcopenia is a condition in which the body starts losing its muscle mass and normal strength. Mainly aging people suffer from this condition, which affects their activity level and quality of life. Inadequate amount of nutrition intake coupled with aging often leads to the splanchnic withdrawal of amino acids, decreased muscular reaction to postprandial anabolic response, and vitamin D deficiency. It can be categorized into presarcopenia—loss of muscle mass, sarcopenia—loss of muscle, and severe sarcopenia involves loss of muscles that severely affects the normal functioning of the body. The loss of muscle among the elderly adversely impacts the muscle functions and results in muscle impairment, disability, and mortality. Sarcopenia can be diagnosed with the help of various techniques, such as imaging, MRI, anthropometry or hydrostatic weighing, and dual-energy X-ray absorptiometry (DXA), which can proficiently measure muscle mass. DXA is the most commonly used technique to diagnose sarcopenia.

The various factors projected to drive the growth of sarcopenia market over the forecast timeframe are increasing aging and obese population. The Population Reference Bureau Report in “Aging in the United States” published the number of Americans over the age of 65 or above will be more than double by 2060, i.e., from 46 million in 2016 to over 98 million by 2060. As per the World Health Organization 2016, nearly 650 million adults globally are obese. There is no permanent cure for obesity, which has led to an increase in research and development activities for the development of better treatment options. Furthermore, change in government policies pertaining to research and development activities and disease management activities are further expected to fuel this market in the near future. However, the non-availability of new drugs is expected to limit the sarcopenia market in the upcoming years.

The report provides a company market share analysis to give a broader overview of the key players in the market. In addition, the report also covers key strategic developments in the market, including acquisitions & mergers, new product launches, agreements, partnerships, collaborations & joint ventures, research & development, and regional expansion of major participants involved in the market on a global and regional basis.

Sarcopenia Market: Report Scope

Sarcopenia market is segmented on the basis of supplement type and distribution channel and region.

All the segments have been analyzed based on present and future trends and the market is estimated from 2024 to 2032. 

Based on supplement type, the sarcopenia market is segmented into protein supplements, Vitamin D and Calcium supplements, and Vitamin B12 supplements. Protein supplements are expected to dominate the market over the forecast time period.

Based on the distribution channel, the sarcopenia market is segmented into hospital pharmacies, retail pharmacies, online pharmacies,  and hypermarkets & supermarkets. Online pharmacies are expected to experience a rapid rate of growth over the forecast time period.

By Region, North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa are the key regions of the global sarcopenia market. North America is expected to dominate the sarcopenia market owing to the presence of developed countries and advanced healthcare infrastructure. Europe is expected to closely follow North America in terms of revenue. The Asia Pacific is expected to experience rapid growth in the near future owing to the presence of developing economies over the forecast time period.

The regional segmentation includes the current and forecast demand for North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa with it further divided into major countries, including the U.S., Germany, France, UK, China, Japan, India, and Brazil. This segment includes the demand for the sarcopenia market based on individual segments and treatment in all regions and countries.

Some of the major players operating in the global sarcopenia market include Abbott Laboratories, Pfizer Inc., Eli Lilly and Company, Bayer AG, Sanofi S.A., GlaxoSmithKline plc, Novartis, Cadila Healthcare, and Amway, among others.

Sarcopenia Market: Competitive Analysis

• Abbott Laboratories
• Pfizer Inc.
• Eli Lilly and Company
• Bayer AG
• Sanofi S.A.
• GlaxoSmithKline plc
• Novartis
• Cadila Healthcare
• Amway

This report segments the global sarcopenia market as follows:

Global Sarcopenia Market: Supplement Type Segment Analysis

• Protein Supplement
• Vitamin D & Calcium Supplement
• Vitamin B12 Supplement

Global Sarcopenia Market: Distribution Channel Segment Analysis

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Hypermarket & Supermarket

Global Sarcopenia Market: Regional Segment Analysis

• North America
  • The U.S.
• Europe
  • UK
  • France
  • Germany
• Asia Pacific
  • China
  • Japan
  • India
• Latin America
  • Brazil
• Middle East and Africa